• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Precision Optics Reports First Quarter Fiscal Year 2025 Financial Results

    11/14/24 4:30:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $POCI alert in real time by email

    GARDNER, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, announced operating results on an unaudited basis for its first quarter fiscal year 2025 for the period ended September 30, 2024.

    Q1 2025 Financial Highlights (3 Months Ended September 30, 2024):

    • Revenue was $4.2 million compared to $4.3 million in the same quarter of the previous fiscal year and in line with the expectations provided in September 2024.
    • Engineering revenue was $1.9 million compared to $1.9 million in the same quarter of the previous fiscal year.
    • Production revenue was $2.3 million compared to $2.4 million in the same quarter of the previous fiscal year.
    • Gross margins were 26.6% compared to 33.9% in the same quarter of the previous year.
    • Net loss for the quarter was ($1.3) million, compared to $(0.5) million in the same quarter of the previous year.  
    • Adjusted EBITDA was $(1.0) million for the quarter compared to $(0.2) million in the same quarter of the previous year.  

    Recent Additional Highlights:

    • In October 2024, following FDA 510(k) clearance by its customer for a single-use urological endoscope imaging assembly, POC accelerated the timeline for production deliveries against a $9 million order announced in May 2024. POC currently estimates approximately $3.6 million in product deliveries during its fiscal year ended June 2025.
    • Today, POC announced receipt of an initial $340,000 production order from a large, global medical device company to provide initial stocking quantities of a new single-use ophthalmic endoscope. POC expects follow-on orders to support first year requirements after launch with delivery rates two to three times those of the initial stocking order.

    Precision Optics' CEO, Joseph Forkey, commented, "The first quarter results that we released today were in line with the expectations we provided in September 2024. We are seeing a rapid ramp in production revenue commencing in the current quarter with expectations for substantial revenue growth and dramatic improvements in adjusted EBITDA for the second quarter ending December 31, 2024 and further improvements throughout this fiscal year."

    "Anticipated sequential revenue growth will be driven by a number of product development programs transitioning into production or ramping from recent production levels. We continue to see acceleration of single-use applications. We now have two programs beginning production this year and additional single-use programs in our product development pipeline."

    "We are at an inflection point leading to a high growth production business, building off of the investments we've made over many years to advance our single-use product solutions. This is an exciting time for Precision Optics," Dr. Forkey concluded.

    The following table summarizes the first quarter (unaudited) results for the periods ended September 30, 2024, and 2023:

      Three Months
      Ended September 30
       2024  2023 
    Revenues$4,197,053 $4,321,255 
        
    Gross Profit 1,117,330  1,463,611 
        
    Stock Compensation Expenses 149,364  108,746 
    Other 2,214,907  1,760,158 
    Total Operating Expenses 2,364,271  1,868,904 
        
    Operating Income (Loss) (1,246,941) (405,293)
        
    Net Income (Loss) (1,311,247) (464,415)
        
    Income (Loss) per Share  
     Basic & Fully Diluted$(0.21)$(0.08)
        
       
    Weighted Average Common Shares Outstanding
     Basic & Fully Diluted 6,216,630  6,066,518 



    Conference Call Details

    Date and Time: Thursday, November 14, at 5:00pm ET

    Call-in Information: Interested parties can access the conference call by dialing (844) 735-3662 or

    (412) 317-5705.

    Live Webcast Information: Interested parties can access the conference call via a live webcast, which is available at https://app.webinar.net/rOVEypeYAoR.

    Replay: A teleconference replay of the call will be available until November 21, 2024, at (877) 344-7529 or (412) 317-0088, replay access code 7879688. A webcast replay will be available at https://app.webinar.net/rOVEypeYAoR.

    About Precision Optics Corporation

    Founded in 1982, Precision Optics is a vertically integrated optics company primarily focused on leveraging its proprietary micro-optics and 3D imaging technologies to the healthcare and defense/aerospace industries by providing services ranging from new product concept through mass manufacture. Utilizing its leading-edge in-house design, prototype, regulatory and fabrication capabilities as well as its Lighthouse Imaging division's electronic imaging expertise and its Ross Optical division's high volume world-wide sourcing, inspecting and production resources, the Company designs and manufactures next-generation product solutions for the most challenging customer requirements. Within healthcare, Precision Optics enables next generation medical device companies around the world to meet the increasing demands of the surgical community who require more enhanced and smaller imaging systems for minimally invasive surgery, including single-use medical devices, as well as 3D endoscopy systems to support the rapid proliferation of surgical robotic systems. In addition to these next generation applications, Precision Optics has supplied top tier medical device companies with a wide variety of optical products for decades, including complex endocouplers and specialized endoscopes. The Company is also leveraging its technical proficiency in micro-optics to enable leading edge defense/aerospace applications which require the highest quality standards and the optimization of size, weight and power. For more information, please visit www.poci.com.

    Non-GAAP Financial Measures

    Precision Optics has provided in this press release financial information that has not been prepared in accordance with accounting principles generally accepted in the Unites States of America ("non-GAAP"). The non-GAAP financial measure is Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization). Adjusted EBITDA also excludes from Net Income (Loss) the effect of stock-based compensation AND DEPRECIATION, AMORTIZATION AND INTEREST EXPENSE.

    This non-GAAP financial measure assists Precision Optics management in comparing its operating performance over time because certain items may obscure the underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete acquisition or restructuring plans that are fundamentally different from the ongoing productivity of the Company. Precision Optics management also believes that presenting this measure allows investors to view its performance using the same measures that the Company uses in evaluating its financial and business performance and trends.

    Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of the non-GAAP financial measure presented above to GAAP results has been provided in the financial tables included with this press release.

    About Forward-Looking Statements

    This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express the Company's intentions, beliefs, expectations, strategies, predictions or any other statements related to the Company's future activities or future events or conditions. Forward-looking statements in this press release include, without limitation, future levels of expected product deliveries and projections related to future EBITDA goals. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by the Company's management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous risk factors, including those risks discussed in the Company's annual report on Form 10-K and in other documents that we file from time to time with the SEC. Any forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement, except as required by law.

    Company Contact:

    PRECISION OPTICS CORPORATION

    22 East Broadway

    Gardner, Massachusetts 01440-3338

    Telephone: 978-630-1800

    Investor Contact:

    LYTHAM PARTNERS, LLC

    Robert Blum

    Telephone: 602-889-9700

    [email protected]

      
    PRECISION OPTICS CORPORATION, INC.

    CONSOLIDATED BALANCE SHEETS

    (UNAUDITED)
     
      
      September 30,  June 30, 
      2024  2024 
    ASSETS        
    Current Assets:        
    Cash and cash equivalents $635,572  $405,278 
    Accounts receivable, net of allowance for doubtful accounts of $103,224 at September 30, 2024 and $118,872 at June 30, 2024  3,123,595   3,545,491 
    Inventories  3,460,621   2,868,100 
    Prepaid expenses  288,475   299,364 
    Total current assets  7,508,263   7,118,233 
             
    Fixed Assets:        
    Machinery and equipment  3,346,694   3,341,194 
    Leasehold improvements  819,954   810,914 
    Furniture and fixtures  426,234   416,425 
       4,592,882   4,568,533 
    Less—accumulated depreciation and amortization  4,123,250   4,074,960 
    Net fixed assets  469,632   493,573 
             
    Operating lease right-to-use asset  146,247   189,999 
    Patents, net  290,309   286,559 
    Goodwill  8,824,210   8,824,210 
    Total other assets  9,260,766   9,300,768 
    TOTAL ASSETS $17,238,661  $16,912,574 
             
    LIABILITIES AND STOCKHOLDERS' EQUITY        
    Current Liabilities:        
    Revolving line of credit $500,000  $1,000,000 
    Current portion of capital lease obligation  38,886   41,113 
    Current maturities of long-term debt  285,901   276,928 
    Accounts payable  2,143,351   1,397,313 
    Contract liabilities  1,106,546   1,172,350 
    Accrued compensation and other  1,115,135   840,662 
    Operating lease liability  146,247   178,450 
    Total current liabilities  5,336,066   4,906,816 
             
    Capital lease obligation, net of current portion  18,384   27,369 
    Long-term debt, net of current maturities and debt issuance costs  1,746,764   1,899,052 
    Operating lease liability, net of current portion  -   11,549 
    Total liabilities  7,101,214   6,844,786 
             
    Stockholders' Equity:        
    Common stock, $0.01 par value: 50,000,000 shares authorized; issued and outstanding – 6,350,170 shares at September 30, 2024 and 6,073,939 at June 30, 2024  63,502   60,739 
    Additional paid-in capital  62,575,576   61,197,433 
    Accumulated deficit  (52,501,631)  (51,190,384)
    Total stockholders' equity  10,137,447   10,067,788 
             
    TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $17,238,661  $16,912,574 



      
    PRECISION OPTICS CORPORATION, INC.

    CONSOLIDATED STATEMENTS OF OPERATIONS

    FOR THE THREE MONTHS ENDED

    SEPTEMBER 30, 2024 AND 2023

    (UNAUDITED)
     
      
      Three Months

    Ended September 30,
     
      2024  2023 
    Revenues $4,197,053  $4,321,255 
             
    Cost of Goods Sold  3,079,723   2,857,644 
    Gross Profit  1,117,330   1,463,611 
             
    Research and Development Expenses  400,659   212,758 
    Selling, General and Administrative Expenses  1,963,612   1,656,146 
    Total Operating Expenses  2,364,271   1,868,904 
             
    Operating Loss  (1,246,941)  (405,293)
             
    Interest Expense  (64,306)  (59,122)
             
    Net Loss $(1,311,247) $(464,415)
             
    Loss Per Share:        
    Basic & Fully Diluted $(0.21) $(0.08)
             
    Weighted Average Common Shares Outstanding:        
    Basic & Fully Diluted  6,216,630   6,066,518 



      
    PRECISION OPTICS CORPORATION, INC.

    CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

    FOR THE THREE MONTHS ENDED

    SEPTEMBER 30, 2024 AND 2023

    (UNAUDITED)
     
      
      Three Month Period Ended September 30, 2024 
      Number of

    Shares
       Common

    Stock

     Additional

    Paid-in

    Capital
      Accumulated

    Deficit
      Total

    Stockholders'

    Equity
     
                    
    Balance, July 1, 2024  6,073,939  $60,739  $61,197,433  $(51,190,384) $10,067,788 
    Issuance of common stock in registered direct offering  265,868   2,659   1,201,883       1,204,542 
    Proceeds from exercise of stock option  10,363   104   26,896       27,000 
    Stock-based compensation  –   –   149,364   –   149,364 
    Net loss  –   –   –   (1,311,247)  (1,311,247)
    Balance, September 30, 2024  6,350,170  $63,502  $62,575,576  $(52,501,631) $10,137,447 



                    
      Three Month Period Ended September 30, 2023 
      Number of

    Shares
      Common

    Stock
      Additional

    Paid-in

    Capital
      Accumulated

    Deficit
      Total

    Stockholders'

    Equity
     
                    
    Balance, July 1, 2023  6,066,518  $60,665  $60,224,934  $(48,239,007) $12,046,592 
    Stock-based compensation  –   –   108,746       108,746 
    Net loss  –   –   –   (464,415)  (464,415)
    Balance, September 30, 2023  6,066,518  $60,665  $60,333,680  $(48,703,422) $11,690,923 



     
    PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES
    RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
    ADJUSTED EBITDA
     
      Three Months
    September 30,
      2024   2023 
    Net Income (loss) (GAAP) $(1,311,247)  $(464,415)
            
    Stock based compensation  149,364    108,746 
            
    Depreciation and amortization  48,290    51,564 
            
    State Income Taxes  -    - 
            
    Interest expense  64,306    59,122 
            
    Adjusted EBITDA (non-GAAP) $(1,049,287)  $(244,983)
            


    Primary Logo

    Get the next $POCI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $POCI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $POCI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Precision Optics Schedules Second Quarter of Fiscal Year 2026 Conference Call for February 17, 2026

    GARDNER, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's second quarter fiscal year 2026 financial results on Tuesday, February 17, 2026, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-Q after the close of the market on Tuesday, February 17, 2026, followed by the conference call. Conference Call Details Date and Time: Tuesday, February 17, 2026, at 5:00 p.m. ET. Call-in Information: Interest

    2/13/26 9:00:00 AM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Precision Optics Reports First Quarter Fiscal Year 2026 Financial Results

    GARDNER, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, announced operating results on an unaudited basis for its first quarter fiscal year 2026 for the period ended September 30, 2025. Q1 2026 Financial Highlights (3 Months Ended September 30, 2025): Revenue was $6.7 million, a quarterly record, compared to $4.2 million in the same quarter of the previous fiscal year, representing growth of approximately 59%.Production revenue was $6.0 million, a quarterly record, compared to $2.6 million in the same quarter of the previous fis

    11/13/25 4:30:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Precision Optics Announces Product Development Agreement to Develop Custom High-End Borescope for Jet Engines

    GARDNER, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced the receipt of a product development order to design and build a next generation borescope system to be used to inspect the inside of jet engines from a large aerospace and defense company. The system involves the development of a high-end, small-diameter borescope designed in multiple configurations to measure critical components inside jet engines in the field. It will deliver greater-than-1080p HD resolution performance and is engineered to withstand the e

    11/11/25 9:00:00 AM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Coll Wayne M bought $107,905,271 worth of shares (4,317 units at $24,995.43) (SEC Form 4)

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    8/16/24 4:30:31 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Executive Officer Forkey Joseph Norman bought $17,228,869 worth of shares (1,725 units at $9,987.75), increasing direct ownership by 1% to 122,572 units (SEC Form 4)

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    8/16/24 4:30:30 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Operating Officer Lawande Mahesh bought $17,248,850 worth of shares (1,726 units at $9,993.54) (SEC Form 4)

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    8/16/24 4:30:33 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Financials

    Live finance-specific insights

    View All

    Precision Optics Schedules Second Quarter of Fiscal Year 2026 Conference Call for February 17, 2026

    GARDNER, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's second quarter fiscal year 2026 financial results on Tuesday, February 17, 2026, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-Q after the close of the market on Tuesday, February 17, 2026, followed by the conference call. Conference Call Details Date and Time: Tuesday, February 17, 2026, at 5:00 p.m. ET. Call-in Information: Interest

    2/13/26 9:00:00 AM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Precision Optics Schedules First Quarter of Fiscal Year 2026 Conference Call for November 13, 2025

    GARDNER, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's first quarter fiscal year 2026 financial results on Thursday, November 13, 2025, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-Q after the close of the market on Thursday, November 13, 2025, followed by the conference call. Conference Call Details Date and Time: Thursday, November 13, 2025, at 5:00 p.m. ET. Call-in Information: Intere

    11/6/25 4:15:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Precision Optics Schedules Fourth Quarter and Fiscal Year 2025 Conference Call for September 29, 2025

    GARDNER, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's fourth quarter and fiscal year 2025 financial results on Monday, September 29, 2025, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-K after the close of the market on Monday, September 29, 2025, followed by the conference call. Conference Call Details Date and Time: Monday, September 29, 2025, at 5:00 p.m. ET. Call-in Information: Int

    9/24/25 4:15:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Coll Wayne M was granted 5,528 shares, increasing direct ownership by 62% to 14,406 units (SEC Form 4)

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    1/5/26 4:15:15 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Director Pellegrino Joseph P Jr

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    11/19/25 9:11:13 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Director Woodward Peter H

    4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

    11/19/25 4:34:59 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    SEC Filings

    View All

    SEC Form DEFR14A filed by Precision Optics Corporation Inc.

    DEFR14A - PRECISION OPTICS CORPORATION, INC. (0000867840) (Filer)

    2/3/26 4:46:16 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form DEFA14A filed by Precision Optics Corporation Inc.

    DEFA14A - PRECISION OPTICS CORPORATION, INC. (0000867840) (Filer)

    2/2/26 4:16:05 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form DEF 14A filed by Precision Optics Corporation Inc.

    DEF 14A - PRECISION OPTICS CORPORATION, INC. (0000867840) (Filer)

    2/2/26 4:15:33 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Leadership Updates

    Live Leadership Updates

    View All

    Precision Optics Appoints Joseph P. Pellegrino, Jr. to Board of Directors

    GARDNER, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Joseph P. "JJ" Pellegrino, Jr. to its Board of Directors. Mr. Pellegrino, who will also serve as Chairman of the Board's Audit Committee, brings decades of operational and financial experience as well as an extensive knowledge of the medical device industry to the board. Mr. Pellegrino most recently served as Chief Financial Officer of LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of devices, implants and services for the treatm

    3/20/25 9:00:00 AM ET
    $LMAT
    $POCI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    Precision Optics Appoints Buell Duncan to Board of Directors; Dr. Richard Miles Retires from Board

    GARDNER, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Buell Duncan to its Board of Directors. Mr. Duncan brings decades of executive leadership and strategic expertise, further strengthening the Company's commitment to innovation and growth. With an extensive career in the technology and business sectors, Mr. Duncan held senior leadership positions at a number of IBM global business units from 1992 through 2020 where he was instrumental in driving marketing, strategy, and business deve

    3/4/25 4:30:00 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Precision Optics Appoints Clay Schwabe as VP of Sales and Marketing

    GARDNER, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today announced the appointment of Clay Schwabe, as the Company's Vice President of Sales and Marketing. Mr. Schwabe has over fifteen years of experience in medical device market access, sales, sales management, global product marketing, and commercialization. He is an emerging technologies specialist with experience in early-stage commercialization of minimally invasive surgical products and procedures. Most recently, he served as VP Business Development, Commercial Strategy, CRO, an

    7/8/24 9:00:00 AM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $POCI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Precision Optics Corporation Inc.

    SC 13G/A - PRECISION OPTICS CORPORATION, INC. (0000867840) (Subject)

    11/13/24 5:53:45 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Precision Optics Corporation Inc.

    SC 13G - PRECISION OPTICS CORPORATION, INC. (0000867840) (Subject)

    5/17/24 5:03:18 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care